All In Biotech

Drug Trial Radar · NCT07176689

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

A Single-Arm, Open-Label Phase 4 Study of Nirogacestat in Adult Premenopausal Females With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Sep 17, 2025

Primary completion

Feb 26, 2031

Study completion Feb 26, 2031

Sponsor

Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.

Conditions

  • Desmoid Tumor
  • Aggressive Fibromatosis

Interventions

  • NirogacestatDrug

    Nirogacestat oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ovarian function recovery rate of ovarian toxicity (OT) treatment-emergent adverse events (TEAEs)Time frame: Up to 24 cycles (each cycle is 28 days) of treatment and up to 2 years in the Clinical Follow-up Period

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc (CUSL)

    Brussels, Belgium · Recruiting

  • Universitaetsmedizin Mannheim

    Mannheim, Germany · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

    Bologna, Italy · Recruiting

  • IRCCS Istituto Ortopedico Rizzoli di Bologna

    Bologna, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori Milano

    Milan, Italy · Recruiting

  • Istituto Nazionale Tumori I.R.C.C.S- Fondazione G. Pascale

    Naples, Italy · Recruiting

  • Policlinico Universitario Campus Bio-Medico

    Roma, Italy · Recruiting

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.

    Meldola, Forli-Cesena, Italy · Recruiting

  • La Fondazione e l'Istituto di Candiolo

    Candiolo, Torino, Italy · Recruiting

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)

    Amsterdam, Netherlands · Recruiting

  • Academisch Ziekenhuis Leiden

    Leiden, Netherlands · Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain · Recruiting

  • Institut Catala d'Oncologia

    Barcelona, Spain · Recruiting

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain · Recruiting

  • Hospital Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain · Recruiting

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain · Recruiting

  • Cambridge University - Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • University College London Hospital

    London, United Kingdom · Recruiting

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.